Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16513137 | 0.83 | GDA (0.64) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL16513149 | 0.81 | FGFR1 (0.59) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL5857483 | 0.74 | GDA (0.57) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL219478 | 0.74 | GDA (1.00) | FGFR1FGFR2GDAKDM4EGAA | |
| SCHEMBL29123832 | 0.72 | KDM4E (0.68) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL8591402 | 0.71 | FGFR1 (0.51) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL9581457 | 0.70 | GDA (0.89) | FGFR1FGFR2GDAKDM4EGAA | |
| SCHEMBL14716598 | 0.69 | FGFR1 (0.51) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL14716735 | 0.69 | FGFR1 (0.53) | FGFR1FGFR2GDAFGFR3KDM4E | |
| SCHEMBL24802600 | 0.68 | ADORA3 (0.56) | FGFR1FGFR2GDAFGFR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222578802-U | Diacetyl guanine production high-efficient drying device | 洛阳德胜生物科技股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-115724845-B | Triacetyl ganciclovir preparation method of pyrrosir | 湖北省宏源药业科技股份有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-114047262-B | Method for separating and measuring easily-hydrolyzed large polar compound | 湖北省宏源药业科技股份有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-221999833-U | Accurate temperature control device during diacetyl guanine reaction | 洛阳德胜生物科技股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-113929580-B | Method for recovering side chains in ganciclovir condensate mother liquor | 湖北省宏源药业科技股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-114478531-B | Method for recycling ganciclovir condensate synthetic mother liquor | 湖北省宏源药业科技股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-118561846-A | Acyclovir preparation method of pyrrosia lingua | 拓新药业集团股份有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-221445833-U | Diacetyl guanine concentration detector | 通辽德胜生物科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-221131020-U | Rectifying column for diacetylguanine production | 新乡瑞诚科技股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-115367745-B | Tungsten-containing substance hybridization and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2023-11-24 | — | — | CN | claimed |
| EP-1453833-A2 | A PROCESS FOR THE PREPARATION OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1,3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES, LTD. (IN) | 2004-09-08 | — | — | EP | claimed |
| WO-2004048380-A1 | PROCESS FOR THE SYNTHESIS OF GANCICLOVIR | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-10 | — | — | WO | claimed |
| US-20040102628-A1 | Process for the synthesis of ganciclovir | RANBAXY LABORATORIES LIMITED (IN) | 2004-05-27 | — | — | US | claimed |
| WO-2004039808-A2 | PROCESS FOR THE PREPARATION OF GANCICLOVIR | RANBAXY LABORATORIES LIMITED (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2003033498-A2 | A PROCESS FOR THE TREATMENT OF GANCICLOVIR INTERMEDIATE N2-ACETYL-9-(1, 3-DIACETOXY-2-PROPOXYMETHYL) GUANINE | RANBAXY LABORATORIES LIMITED (IN) | 2003-04-24 | — | — | WO | claimed |
| EP-0806425-B1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LAB LTD (IN) | 2001-08-29 | — | — | EP | claimed |
| US-5821367-A | REACTING A DIACYLGUANINE AND AN ALKYLATING AGENT IN THE ABSENCE OF AN ACID CATALYST AND A SOLVENT | LUPIN LABORATORIES LIMITED (IN) | 1998-10-13 | — | — | US | claimed |
| EP-0806425-A1 | An improved regiospecific process for synthesis of acyclic nucleosides | LUPIN LABORATORIES LIMITED (IN) | 1997-11-12 | — | — | EP | claimed |
| WO-1997024357-A1 | PROCESS FOR SYNTHESIS AND PURIFICATION OF A COMPOUND USEFUL IN THE PREPARATION OF ACYCLOVIR | MALLINCKRODT CHEMICAL, INC. (US) | 1997-07-10 | — | — | WO | claimed |
| US-5583225-A | REACTING N2, N9-DIPROTECTED GUANINE WITH DIACETOXYPROPANE IN THE PRESENCE OF A MIXTURE OF AN ACID AND ACETIC ANHYDRIDE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102628-A1 | Process for the synthesis of ganciclovir | TYMP, MTAP, TPMT | FGFR1 2811/4885FGFR2 2593/4885GDA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.